拓新药业 reported revenue of ¥0.21B for the period ended 2026-06-30, +16.2% year on year. Net income was ¥-0.03B, a -13.2% net margin on a 19.5% gross margin. The largest revenue line is 医药中间体 at 41% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.21B | +16.2% |
| Gross profit | ¥0.04B | — |
| Operating income | ¥-0.03B | — |
| Net income | ¥-0.03B | — |
| Gross margin | 19.5% | Net margin -13.2% |
| Revenue Q/Q | +28.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医药中间体 | ¥0.09B | 41.0% |
| 原料药 | ¥0.06B | 27.9% |
| CMO/CDMO | ¥0.04B | 18.2% |
| 功能食品原料 | ¥0.03B | 12.9% |
| 其他 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.17B | 80.5% |
| R&D | ¥0.02B | 10.0% |
| SG&A | ¥0.04B | 20.4% |
| Tax & other | ¥-0.00B | -0.3% |
| Item | Amount |
|---|---|
| Total assets | ¥1.63B |
| Total liabilities | ¥0.17B |
| Shareholders' equity | ¥1.46B |
| Equity / assets | 89.3% |
| Operating cash flow | ¥-0.00B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 16% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华润材料 ・ 深城交 ・ 争光股份 ・ 华兰股份 ・ 广立微 ・ 百诚医药 ・ 天益医疗 ・ 金埔园林 ・ 雅创电子 ・ 风光股份 ・ 明月镜片 ・ 兆讯传媒
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies